5-alpha reductase deficiency market seen reaching $2.36 billion by 2030

The Business Research Company says the global 5-alpha reductase deficiency market will grow from $1.64 billion in 2026 to $2.36 billion by 2030, driven by better genetic testing, screening programs and specialty care. North America led the market in 2025 as genomics research and rare-disease diagnosis expand.

Why it matters: - The 5-alpha reductase deficiency market is tied to rare-disease diagnosis, genetic testing and hormone therapy access. - Faster detection and broader screening could change care paths for patients with this disorder, which affects male sexual development before birth and during puberty. - Market growth also signals rising investment in specialized endocrinology, urology and genetic endocrinology services.

What happened: - The Business Research Company projected the global 5-alpha reductase deficiency market will rise from $1.64 billion in 2026 to $2.36 billion by 2030. - The forecast implies a 9.5% compound annual growth rate through 2030. - The market report also said the market reached $1.5 billion in 2025. - North America was the dominant region in 2025. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

The details: - The report said growth is being supported by technological progress in gene sequencing. - Newborn and carrier screening programs are expanding. - Personalized hormone therapies are drawing more focus. - Specialty clinics for rare diseases are increasing. - Research in genetic endocrinology is intensifying. - The report expects earlier diagnosis of 5-alpha reductase deficiency. - Broader use of genetic and hormonal tests is one of the main trends. - Growth in specialized endocrinology and urology services is also expected. - Availability of hormone replacement treatments is improving. - People with 5-alpha reductase deficiency produce too little dihydrotestosterone, or DHT. - DHT is essential for proper male sexual differentiation and development. - The hormone shortage can lead to atypical sexual characteristics and development challenges. - A key growth driver is the surge in genomics research and development. - Genomics helps identify the genetic mutations that cause the disorder. - U.S. research and development spending rose from $892 billion in 2022 to $940 billion in 2023, according to NCSES data cited in the report. - The report said that $48 billion increase is helping fuel genomics research. - The 2026 report edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables. - The report offers a free sample and full report online: Download the sample report and View the full report.

Between the lines: - The market outlook reflects a shift from diagnosis based mainly on clinical evaluation toward more genetics-driven and hormone-based testing. - Rare-disease markets tend to grow when screening widens and specialty care becomes easier to access. - The emphasis on genomics suggests the biggest upside may come from earlier identification rather than from large patient volumes.

What's next: - The market is expected to keep growing as newborn screening, carrier screening and gene sequencing expand. - More specialty clinics and improved hormone therapies could support treatment uptake through 2030. - The report points to continued research activity in genetics and endocrinology as a likely driver of future market expansion.